Order Article Reprints

Mora J, Castañeda A, Gorostegui M, Varo A, Perez-Jaume S, Simao M, Muñoz JP, Garraus M, Larrosa C, Salvador N, et al. Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use—Updated Outcome Report. Cancers. 2023; 15(9):2535. https://doi.org/10.3390/cancers15092535

Mora, Jaume, Alicia Castañeda, Maite Gorostegui, Amalia Varo, Sara Perez-Jaume, Margarida Simao, Juan Pablo Muñoz, Moira Garraus, Cristina Larrosa, Noelia Salvador, and et al. 2023. "Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use—Updated Outcome Report" Cancers 15, no. 9: 2535. https://doi.org/10.3390/cancers15092535

Mora, J., Castañeda, A., Gorostegui, M., Varo, A., Perez-Jaume, S., Simao, M., Muñoz, J. P., Garraus, M., Larrosa, C., Salvador, N., Lavarino, C., Krauel, L., & Mañe, S. (2023). Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use—Updated Outcome Report. Cancers, 15(9), 2535. https://doi.org/10.3390/cancers15092535